Dated disclosed rounds · latest 2024-10-01
Series B
Enara Bio
Immuno-oncology (TCR-based therapeutics, 'Dark Antigens')
VerifiedSeries BOxford
- Companies House
- 10469748
- GLEIF LEI
- Not matched
- Latest evidence
- 2024-10-01
- Evidence snapshot
- 2026-08-25
Exact award notices · latest No exact award match
2026-08-01
Jun 2026
Signals organise dated evidence; they do not score growth, revenue, creditworthiness or investment performance.
Evidence timeline
3 dated observations
Funding, procurement, registry and identifier records are placed on one chronology. Each row says whether it is a source fact, a record observation or reference metadata; no inferred event is inserted.
RegistryRecord observation Status observed: Active
Snapshot evidence only; this row does not claim the status changed on this date.
FundingSource fact Series B
$32.5M · 6 named investors
RegistryRegistry fact Company incorporated
ENARA BIO LIMITED · company 10469748
Latest disclosed round
Series B
- Date
- 2024-10-01
- Amount
- USD 32.5m
- Sector
- Biotech & techbio
- Companies House
- 10469748
- ONS region
- South East
Evidence status
Directory ready
- Identity
- Verified
- Match
- High — exact company number and aligned registered name
- Operating status
- active
- Data origins
- Core directory, Growth Network, Live Chris T D1
Capital network
6 linked investors
Lead, participant, lender and other retained roles remain distinct where the source supports them. Every relationship below names its source layer, observation date, match method and publication state.
M VenturesleadPfizer VenturesleadRA CapitalparticipantSamsara BioCapitalparticipantSV Health InvestorsparticipantThe Francis Crick Instituteparticipant
| Investor | Role | Date | Source | Match / state |
|---|---|---|---|---|
| M Ventures | lead | 2024-10-01 | Enarabio ↗ · M Ventures ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Pfizer Ventures | lead | 2024-10-01 | Enarabio ↗ · M Ventures ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| RA Capital | participant | 2024-10-01 | Enarabio ↗ · M Ventures ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| Samsara BioCapital | participant | 2024-10-01 | Enarabio ↗ · M Ventures ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| SV Health Investors | participant | 2024-10-01 | Enarabio ↗ · M Ventures ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
| The Francis Crick Institute | participant | 2024-10-01 | Enarabio ↗ · M Ventures ↗ | reviewed canonical company and investor alias resolutionsource-linked · published |
Funding record
1 disclosed round
Open a dated round to move directly between the company, named investors and source publication.
| Date | Stage | Amount | Investors | Named sources |
|---|---|---|---|---|
| 2024-10-01 | Series B | $32.5M | Pfizer Ventures · M Ventures · RA Capital · Samsara BioCapital · SV Health Investors · The Francis Crick Institute | Enarabio ↗ · M Ventures ↗ |
Companies House status and filing snapshot
ENARA BIO LIMITED
Exact company-number match from the public register. The retained status is active. Filing dates and SIC codes are registry context, not a credit or investment-quality assessment.
Registered record
- Status
- Active
- Company type
- Private Limited Company
- Country of origin
- United Kingdom
- Incorporated
- 2016-11-08
- Dissolved
- Not applicable
- Company number
- 10469748
Filing context
- Accounts category
- GROUP
- Accounts made up to
- 2024-12-31
- Next accounts due
- 2026-09-30
- Confirmation made up to
- 2025-11-07
- Registry snapshot
- 2026-08-01
- Live check
- Bulk snapshot only
Former registered names: ERVAXX LIMITED
72110Research and experimental development on biotechnology
Traceability
Source trail
Funding and investor claims retain named public-source links. This is a dated research snapshot, not a live cap table.